GlassScriptPhysician profile
Nitin Tiwari
NPI 1720433592
$2,063.88
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $101 · 2021: $781 · 2022: $398 · 2023: $713 · 2024: $71.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.58 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $568.13 | 2020-2023 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $283.41 | 2021-2024 | Tremfya |
| Bayer Healthcare Pharmaceuticals INC. | $211.19 | 2021-2023 | |
| Pfizer INC. | $148.21 | 2020-2023 | |
| Lilly USA, LLC | $146.09 | 2021-2023 | Taltz, Olumiant |
| Vifor Pharma, INC. | $130.24 | 2021 | |
| Amgen INC. | $82.24 | 2021-2023 | Otezla |
| Novartis Pharmaceuticals Corporation | $73.55 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $70.14 | 2023 | Sotyktu |
| Pharmacosmos Therapeutics INC. | $40.49 | 2021 | |
| Arcutis Biotherapeutics, INC. | $33.41 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $27.20 | 2023 | Vtama |
| Otsuka America Pharmaceutical, INC. | $26.73 | 2022-2024 | Jynarque |
| Opko Pharmaceuticals, LLC | $26.58 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $25.04 | 2023 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $24.88 | 2023 | Adbry |
| Helsinn Therapeutics (U.S.), INC. | $22.94 | 2021 | |
| Ardelyx, INC. | $18.39 | 2023 | Ibsrela |
| Krystal Biotech INC | $17.90 | 2023 | Vyjuvek |
| Alnylam Pharmaceuticals INC. | $16.78 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.17 | 2023 | Siliq |
| Ucb, INC. | $15.84 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.18 | 2020 | |
| Mylan Institutional INC. | $12.96 | 2023 | Hulio |
| Galderma Laboratories, L.P. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Tiwari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.